Related references
Note: Only part of the references are listed.Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)
Mouhamad Nasser et al.
EUROPEAN RESPIRATORY JOURNAL (2021)
The potential indicators for pulmonary fibrosis in survivors of severe COVID-19
Wenhui Huang et al.
JOURNAL OF INFECTION (2021)
Assessing the Impact of Comprehensive Medication Management on Achievement of the Quadruple Aim
M. Shawn McFarland et al.
AMERICAN JOURNAL OF MEDICINE (2021)
Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases
Charles Khouri et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2021)
Pulmonary function and health-related quality of life after COVID-19 pneumonia
S. Van der Sar-van der Brugge et al.
RESPIRATORY MEDICINE (2021)
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19
Alessia Alunno et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities
Antonella Caminati et al.
INTERNAL AND EMERGENCY MEDICINE (2021)
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials
Giacomo Sgalla et al.
EXPERT OPINION ON EMERGING DRUGS (2021)
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
Juergen Behr et al.
LANCET RESPIRATORY MEDICINE (2021)
Prevalence of adverse drug reactions in the primary care setting: A systematic review and meta-analysis
Widya N. Insani et al.
PLOS ONE (2021)
Adverse drug reactions in primary care: a scoping review
H. Khalil et al.
BMC HEALTH SERVICES RESEARCH (2020)
Chronic Disease Decision Making and What Matters Most
Terri R. Fried et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2020)
Adverse Outcomes of Polypharmacy in Older People: Systematic Review of Reviews
Laurie E. Davies et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2020)
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia
Qun Li et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The natural history of progressive fibrosing interstitial lung diseases
K.K. Brown et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Pulmonary fibrosis secondary to COVID-19: a call to arms?
Paolo Spagnolo et al.
Lancet Respiratory Medicine (2020)
Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration?
Mathew Suji Eapen et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
COVID-19: Disease, management, treatment, and social impact
Imran Ali et al.
SCIENCE OF THE TOTAL ENVIRONMENT (2020)
Pulmonary fibrosis in the aftermath of the COVID-19 era (Review)
Eirini Vasarmidi et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2020)
Spectrum of Fibrotic Lung Diseases
Marlies Wijsenbeek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes
Florian Klomp et al.
PHARMACEUTICS (2020)
Lactate dehydrogenase elevations is associated with severity of COVID-19: a meta-analysis
Xiao-Yun Chen et al.
CRITICAL CARE (2020)
Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies
Ademola S. Ojo et al.
PULMONARY MEDICINE (2020)
An overview of prevalence, determinants and health outcomes of polypharmacy
Mina Khezrian et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2020)
Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
Laurie D. Snyder et al.
BMJ OPEN RESPIRATORY RESEARCH (2020)
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
Oliver Distler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone
Luca Richeldi et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
Jaana Kaunisto et al.
ERJ OPEN RESEARCH (2019)
Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis
Wu Yi Zheng et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Impact of Lung Function Decline on Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis (IPF)
M. Kreuter et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA
Imre Noth et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Polimedication: applicability of a computer tool to reduce polypharmacy in nursing homes
Tomas M. Garcia-Caballero et al.
INTERNATIONAL PSYCHOGERIATRICS (2018)
Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece
Argyrios Tzouvelekis et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2018)
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Eva Brunnemer et al.
RESPIRATION (2018)
Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
Vincent Cottin et al.
ERJ OPEN RESEARCH (2018)
Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials
Steven D. Nathan et al.
BMJ OPEN RESPIRATORY RESEARCH (2018)
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis Results of the INJOURNEY Trial
Carlo Vancheri et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Drug Idiosyncrasy Due To Pirfenidone Presenting as Acute Liver Failure: Case Report and Mini-Review of the Literature
Nipun Verma et al.
HEPATOLOGY COMMUNICATIONS (2018)
Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions
Jonathan A. Galli et al.
RESPIROLOGY (2017)
Longitudinal Real-World Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
Argyrios Tzouvelekis et al.
FRONTIERS IN MEDICINE (2017)
Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
Hannah Toellner et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2017)
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
Paul W. Noble et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
Carlo Albera et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer
Claudia Dallinger et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials
Luca Richeldi et al.
RESPIRATORY MEDICINE (2016)
Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
Gareth Hughes et al.
JOURNAL OF CLINICAL MEDICINE (2016)
Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review
John Hutchinson et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
Takashi Ogura et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Tamera Corte et al.
RESPIRATORY RESEARCH (2015)
Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
Vincent Cottin et al.
EUROPEAN RESPIRATORY REVIEW (2015)
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Drug Interactions-Principles, Examples and Clinical Consequences
Ingolf Cascorbi
DEUTSCHES ARZTEBLATT INTERNATIONAL (2012)
Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis
Ganesh Raghu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble et al.
LANCET (2011)
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy chinese volunteers
Shaojun Shi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Share Paper
